On March 1, Fosun Pharma announced that the board of directors agreed to issue H shares and listed on the main board of Hong Kong Stock Exchange.

It is reported that the size of the H shares issued will not exceed the 20% of the total equity of the company after the issue, with no more than 15% overallotment option of the issued H shares, the raise fund will be used for the expansion of the international R&D platform, M&A of enterprises at home and abroad, and the development of the existing main business and so on, further optimizing the corporate capital structure. The issue of the H share is still limited to the approval by the shareholders' meeting and supervision department.

In the view of the overall industrial environment, the pharmaceutical industry has developed rapidly since the implementation of the new medical reform policy, not only in aspects of expanding the market size and adjusting the industry structure, but also in the aspect of merger and reorganization, good opportunities for development is provided. Analysts said that the action was complied with trend of the pharmaceutical industry strategic structural adjustment and industrial resources integration, which was beneficial to build internationally competitive large pharmaceutical group. Previously, Sinopharm Group, invested by Fosun Pharma, went public in Hong Kong on September 2009, which was favored by international capital, and became the most highly valued China's state-owned enterprise and the NO. 3 listed company among the international similar enterprises so far. Sinopharm Group quickly M&A local pharmaceutical logistics distribution enterprises through raise funds, and built the nationwide medical system backbone network within one year, further consolidating its leading position in the domestic pharmaceutical commerce.

Yao Fang, president of Fosun Pharma, said that while strengthened its leading position in China's pharmaceutical industry, Fosun Pharma took innovation strategy as the guide to face both international and domestic market, so as to create internationally competitive pharmaceutical enterprise. The future H share platform combined with the existing A-share platform, which not only enrich the financing channels, but is also more advantageous for the company to access to the management norms and standards of the international capital market, improve its international transparency and awareness, optimize corporate management, and further promote the company to form the resource integration ability of the global pharmaceutical market.